Arvinas Inc.

52.48-1.64-3.03%Vol 229.53K1Y Perf -37.72%
Aug 16th, 2022 16:00 DELAYED
BID45.00 ASK84.27
Open53.92 Previous Close54.12
Pre-Market- After-Market52.48
 - -  - -%
Target Price
102.81 
Analyst Rating
Strong Buy 1.40
Potential %
95.90 
Finscreener Ranking
★★★     49.54
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★+     49.70
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★+     62.68
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
27.57 
Earnings Rating
Strong Sell
Market Cap2.79B 
Earnings Date
4th Aug 2022
Alpha0.05 Standard Deviation0.43
Beta1.98 

Today's Price Range

52.420.00

52W Range

34.9098.67

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-9.50%
1 Month
5.28%
3 Months
15.77%
6 Months
-24.36%
1 Year
-37.72%
3 Years
119.67%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARVN52.48-1.6400-3.03
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
-
-247.60
-239.80
-303.80
-
RevenueValueIndustryS&P 500US Markets
91.12M
1.71
32.56
44.90
Earnings HistoryEstimateReportedSurprise %
Q02 2022-1.02-1.32-29.41
Q01 2022-0.85-1.20-41.18
Q04 2021-0.78-1.00-28.21
Q03 20212.85-0.94-132.98
Q02 2021-0.84-1.03-22.62
Q01 2021-0.78-0.84-7.69
Q04 2020-0.78-0.99-26.92
Q03 2020-0.67-0.79-17.91
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.02-13.33Negative
9/2022 QR-0.784.88Positive
12/2022 FY-4.36-18.48Negative
12/2023 FY-4.980.99Positive
Next Report Date-
Estimated EPS Next Report-1.02
Estimates Count12
EPS Growth Next 5 Years %-
Volume Overview
Volume229.53K
Shares Outstanding53.21K
Shares Float44.74M
Trades Count6.51K
Dollar Volume12.19M
Avg. Volume402.06K
Avg. Weekly Volume425.22K
Avg. Monthly Volume384.14K
Avg. Quarterly Volume396.81K

Arvinas Inc. (NASDAQ: ARVN) stock closed at 52.48 per share at the end of the most recent trading day (a -3.03% change compared to the prior day closing price) with a volume of 229.53K shares and market capitalization of 2.79B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 133 people. Arvinas Inc. CEO is John Houston.

The one-year performance of Arvinas Inc. stock is -37.72%, while year-to-date (YTD) performance is -36.11%. ARVN stock has a five-year performance of %. Its 52-week range is between 34.9 and 98.67, which gives ARVN stock a 52-week price range ratio of 27.57%

Arvinas Inc. currently has a PE ratio of -12.20, a price-to-book (PB) ratio of 4.32, a price-to-sale (PS) ratio of 31.60, a price to cashflow ratio of 5.60, a PEG ratio of 2.32, a ROA of -22.73%, a ROC of -37.47% and a ROE of -37.19%. The company’s profit margin is -%, its EBITDA margin is -239.80%, and its revenue ttm is $91.12 Million , which makes it $1.71 revenue per share.

Of the last four earnings reports from Arvinas Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.02 for the next earnings report. Arvinas Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Arvinas Inc. is Strong Buy (1.4), with a target price of $102.81, which is +95.90% compared to the current price. The earnings rating for Arvinas Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arvinas Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arvinas Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.11, ATR14 : 3.50, CCI20 : 22.06, Chaikin Money Flow : 0.08, MACD : 1.97, Money Flow Index : 52.77, ROC : 2.36, RSI : 38.94, STOCH (14,3) : 53.44, STOCH RSI : 0.00, UO : 56.31, Williams %R : -46.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arvinas Inc. in the last 12-months were: Bradley Margus (Sold 29 940 shares of value $2 545 168 ), Briggs Morrison (Option Excercise at a value of $259 008), Briggs Morrison (Sold 20 960 shares of value $1 374 021 ), Briggs W. Morrison (Option Excercise at a value of $518 016), Briggs W. Morrison (Sold 41 920 shares of value $2 766 636 ), Ian Taylor (Option Excercise at a value of $789 388), Ian Taylor (Sold 40 000 shares of value $3 141 062 ), John G. Houston (Option Excercise at a value of $715 040), John G. Houston (Sold 40 000 shares of value $3 525 723 ), Liam Ratcliffe (Option Excercise at a value of $544 531), Liam Ratcliffe (Sold 662 094 shares of value $51 367 310 ), Sean A. Cassidy (Option Excercise at a value of $240 000), Sean A. Cassidy (Sold 15 000 shares of value $1 050 000 ), Timothy M. Shannon (Sold 400 000 shares of value $34 512 491 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (80.00 %)
14 (82.35 %)
15 (88.24 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (20.00 %)
3 (17.65 %)
2 (11.76 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.35
Strong Buy
1.24

Arvinas Inc.

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

CEO: John Houston

Telephone: +1 203 535-1456

Address: 395 Winchester Avenue, New Haven 06511, CT, US

Number of employees: 133

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

65%35%

Bearish Bullish

55%45%

TipRanks News for ARVN

Mon, 09 May 2022 12:42 GMT Analysts Conflicted on These Healthcare Names: Lantheus (LNTH), Arvinas Holding Company (ARVN) and Prestige Consumer Healthcare (PBH)

- TipRanks. All rights reserved.

Wed, 23 Mar 2022 13:15 GMT Arvinas Holding Company (ARVN) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 10:17 GMT Arvinas Holding Company (ARVN) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 09:31 GMT Arvinas Holding Company (ARVN) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits